Im­prop­er Or­ange Book list­ings harm com­pe­ti­tion, FTC says in am­i­cus brief to an­titrust suit

The FTC on Mon­day filed an am­i­cus brief in My­lan Phar­ma­ceu­ti­cals’ an­titrust law­suit al­leg­ing that Sanofi abused the FDA’s Or­ange Book to de­lay and block My­lan’s gener­ic in­sulin from com­pet­ing with Sanofi.

In the suit, filed in May in the US Dis­trict Court for the West­ern Dis­trict of Penn­syl­va­nia, My­lan (now known as Vi­a­tris) al­leges that Sanofi used the Or­ange Book process to block the biosim­i­lar to in­sulin known as Sem­glee from com­pet­ing with Sanofi’s brand­ed prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER